Drug Type siRNA |
Synonyms RBD 2080, RBD2080 |
Target |
Action inhibitors |
Mechanism C3 inhibitors(Complement C3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Kidney Diseases | Phase 1 | China | - | |
| Autoimmune Diseases | IND Approval | Australia | 26 Feb 2025 | |
| Disorder of Complement | Preclinical | China | 08 May 2024 |





